Characterization of human serum butyrylcholinesterase in rhesus monkeys: Behavioral and physiological effects

Neurotoxicology and Teratology

Volumn 34, Issue 3, 2012, Pages 323-330

  Myers, Todd M ^a,b   Sun, Wei ^a   Naik, Ramachandra S ^a   Clark, Matthew G ^a,b   Doctor, Bhupendra P ^a   Saxena, Ashima ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Anti BChE antibody; Clinical blood pathology; Human serum butyrylcholinesterase; Pharmacokinetics; Rhesus monkeys; Serial probe recognition task

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; ANTIDOTE; IMMUNOGLOBULIN G; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUTYRYLCHOLINESTERASE ANTIBODY; CALCIUM; CARBON DIOXIDE; CHLORIDE; CHOLESTEROL; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HUMAN SERUM BUTYRYLCHOLINESTERASE; LACTATE DEHYDROGENASE; PHOSPHORUS; POTASSIUM; PROTEIN; SODIUM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; ATTENTION; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BLOOD CELL COUNT; CHOLINESTERASE BLOOD LEVEL; CLINICAL CHEMISTRY; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; MEAN RESIDENCE TIME; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SHORT TERM MEMORY; TASK PERFORMANCE; ANIMAL; ANIMAL BEHAVIOR; BLOOD; DRUG EFFECT; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; PHYSIOLOGY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATYPICAL LYMPHOCYTE; BASOPHIL; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG SAFETY; EOSINOPHIL COUNT; ERYTHROCYTE; ERYTHROCYTE COUNT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE IMMATURE CELL; LYMPHOCYTE; LYMPHOCYTE COUNT; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MONOCYTE; NEUROPSYCHOLOGY; NEUTROPHIL COUNT; PHOSPHATE BLOOD LEVEL; PLATELETCRIT; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; RED CELL DISTRIBUTION WIDTH; SERIAL PROBE RECOGNITION TASK; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

MACACA MULATTA;

ANIMALS; ANTIDOTES; BEHAVIOR, ANIMAL; BLOOD CELL COUNT; BUTYRYLCHOLINESTERASE; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MACACA MULATTA;

EID: 84859340427     PISSN: 08920362     EISSN: 18729738     Source Type: Journal    
DOI: 10.1016/j.ntt.2012.02.002     Document Type: Article

References (49)

1. Allon N., Raveh L., Gilat E., Cohen E., Grunwald J., Ashani Y. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol Sci 1998, 43:121-128.
2. Ashani Y., Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci 2004, 77:358-367.
3. Ashani Y., Shapira S., Levy D., Wolfe A.D., Doctor B.P., Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol 1991, 41:37-41.
4. Asthana S., Greig N.H., Hegedus L., Holloway H.H., Raffaele K.C., Schapiro M.B., et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1995, 58:299-309.
5. Brandeis R., Raveh L., Grunwald J., Cohen E., Ashani Y. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol Biochem Behav 1993, 46:889-896.
6. Broomfield C.A., Maxwell D.M., Solana R.P., Castro C.A., Finger A.V., Lenz D.E. Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J Pharmacol Exp Ther 1991, 259:633-638.
7. Castro C.A. Primacy and recency effects in rhesus monkeys (Macaca mulatta) using a serial probe recognition task. I. Effects of diazepam. Psychopharmacology (Berl) 1995, 119:421-427.
8. Castro C.A. Primacy and recency effects in rhesus monkeys (Macaca mulatta) using a serial probe recognition task: II. Effects of atropine sulfate. Behav Neurosci 1997, 111:676-682.
9. Castro C.A., Larsen T., Finger A.V., Solana R.P., McMaster S.B. Behavioral efficacy of diazepam against nerve agent exposure in rhesus monkeys. Pharmacol Biochem Behav 1992, 41:159-164.
10. Clark M.G., Sun W., Myers T.M., Bansal R., Doctor B.P., Saxena A. Effects of physostigmine and human butyrylcholinesterase on acoustic startle reflex and prepulse inhibition in C57BL/6J mice. Pharmacol Biochem Behav 2005, 81:497-505.
11. Cohen O., Kronman C., Raveh L., Mazor O., Ordentlich A., Shafferman A. Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Mol Pharmacol 2006, 70:1121-1131.
12. Doctor B.P., Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 2005, 157-158:167-171.
13. Doctor B.P., Raveh L., Wolfe A.D., Maxwell D.M., Ashani Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci Biobehav Rev 1991, 15:123-128.
14. Doctor B.P., Maxwell D.M., Ashani Y., Saxena A., Gordon R.K. New approaches to medical protection against chemical warfare nerve agents. Chemical warfare nerve agents: toxicity at low levels 2001, 191-214. CRC Press, Washington, D.C. S.M. Somani, J.A. Romano (Eds.).
15. Dunn M.A., Sidell F.R. Progress in medical defense against nerve agents. JAMA 1989, 262:649-652.
16. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
17. Evron T., Geyer B.C., Cherni I., Muralidharan M., Kilbourne J., Fletcher S.P., et al. Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath. FASEB J 2007, 21:2961-2969.
18. Fonnum F., Guttormsen D.M. Changes in acetylcholine content of rat brain by toxic doses of di-isopropyl phosphofluoridate. Experientia 1969, 25:505-506.
19. Frederick D.L., Schulze G.E., Gillam M.P., Paule M.G. Acute effects of physostigmine on complex operant behavior in rhesus monkeys. Pharmacol Biochem Behav 1995, 50:641-648.
20. Genovese R.F., Doctor B.P. Behavioral and pharmacological assessment of butyrylcholinesterase in rats. Pharmacol Biochem Behav 1995, 51:647-654.
21. Gentry M.K., Saxena A., Ashani Y., Doctor B.P. Immunochemical characterization of anti-acetylcholinesterase inhibitory monoclonal antibodies. Chem Biol Interact 1993, 87:227-231.
22. Hudzik T.J., Wenger G.R. Effects of drugs of abuse and cholinergic agents on delayed matching-to-sample responding in the squirrel monkey. J Pharmacol Exp Ther 1993, 265:120-127.
23. Laub P.B., Gallo J.M. NCOMP-a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci 1996, 85:393-395.
24. Leadbeater L., Inns R.H., Rylands J.M. Treatment of poisoning by soman. Fundam Appl Toxicol 1985, 5:S225-S231.
25. Lenz D.E., Broomfield C.A., Maxwell D.M., Cerasoli D.M. Nerve agent bioscavengers: protection against high- and low-dose organophosphorus exposure. Chemical warfare agents: toxicity as low levels 2001, 215-243. CRC Press, Washington, D.C. S.M. Somani, J.A. Romano (Eds.).
26. Lenz D.E., Maxwell D.M., Koplovitz I., Clark C.R., Capacio B.R., Cerasoli D.M., et al. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 2005, 157-158:205-210.
27. Matzke S.M., Oubre J.L., Caranto G.R., Gentry M.K., Galbicka G. Behavioral and immunological effects of exogenous butyrylcholinesterase in rhesus monkeys. Pharmacol Biochem Behav 1999, 62:523-530.
28. Maxwell D.M., Castro C.A., De La Hoz D.M., Gentry M.K., Gold M.B., Solana R.P., et al. Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase. Toxicol Appl Pharmacol 1992, 115:44-49.
29. McDonough J.H., Shih T.M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 1997, 21:559-579.
30. McDonough J.H., Jaax N.K., Crowley R.A., Mays M.Z., Modrow H.E. Atropine and/or diazepam therapy protects against soman-induced neural and cardiac pathology. Fundam Appl Toxicol 1989, 13:256-276.
31. Myers T.M., Galbicka G., Sipos M.L., Varadi S., Oubre J.L., Clark M.G. Effects of anticholinergics on serial-probe recognition accuracy of rhesus macaques. Pharmacol Biochem Behav 2002, 73:829-834.
32. Naik R., Liu W., Saxena A. Development and validation of a simple assay for the determination of cholinesterase activity in whole blood of laboratory animals. J Appl Toxicol 2012, 11 pp. doi:10.1002/jat.2730.
33. Penetar D.M., McDonough J.H. Effects of cholinergic drugs on delayed match-to-sample performance of rhesus monkeys. Pharmacol Biochem Behav 1983, 19:963-967.
34. Raveh L., Ashani Y., Levy D., De La Hoz D., Wolfe A.D., Doctor B.P. Acetylcholinesterase prophylaxis against organophosphate poisoning. Quantitative correlation between protection and blood-enzyme level in mice. Biochem Pharmacol 1989, 38:529-534.
35. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 1993, 45:2465-2474.
36. Raveh L., Grauer E., Grunwald J., Cohen E., Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol 1997, 145:43-53.
37. Rosenberg Y., Luo C., Ashani Y., Doctor B.P., Fischer R., Wolfe G., et al. Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase. Life Sci 2002, 72:125-134.
38. Saxena A., Sun W., Luo C., Doctor B.P. Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem Biol Interact 2005, 157-158:199-203.
39. Saxena A., Tipparaju P., Luo C., Doctor B.P. Pilot-scale production of human serum butyrylcholinesterase suitable for use as a bioscavenger against nerve agent toxicity. Process Biochem 2010, 45:1313-1318.
40. Saxena A., Sun W., Fedorko J.M., Koplovitz I., Doctor B.P. Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem Pharmacol 2011, 81:164-169.
41. Shih T.M. Time course effects of soman on acetylcholine and choline levels in six discrete areas of the rat brain. Psychopharmacology 1982, 78:170-175.
42. Taylor P. Anticholinesterase agents. The pharmacological basis of therapeutics 1990, 131. Macmillan, New York. A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).
43. Triggle D.J., Mitchell J.M., Filler R. The pharmacology of physostigmine. CNS Drug Rev 1998, 4:87-136.
44. Wetherell J.R., French M.C. A comparison of the decarbamoylation rates of physostigmine-inhibited plasma and red cell cholinesterases of man with other species. Biochem Pharmacol 1991, 42:515-520.
45. Wilson I.B., Ginsburg S. A powerful reactivator of alkyl phosphate-inhibited acetylcholinesterase. Biochim Biophys Acta 1955, 18:168.
46. Wolfe A.D., Rush R.S., Doctor B.P., Koplovitz I., Jones D. Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam Appl Toxicol 1987, 9:266-270.
47. Wolfe A.D., Blick D.W., Murphy M.R., Miller S.A., Gentry M.K., Hartgraves S.L., et al. Use of cholinesterases as pretreatment drugs for the protection of rhesus monkeys against soman toxicity. Toxicol Appl Pharmacol 1992, 117:189-193.
48. Wolthuis O.L., Groen B., Busker R.W., van Helden H.P. Effects of low doses of cholinesterase inhibitors on behavioral performance of robot-tested marmosets. Pharmacol Biochem Behav 1995, 51:443-456.
49. Worek F., Mast U., Kiderlen D., Diepold C., Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 1999, 288:73-90.